NCT03183570 is a EARLY_PHASE1 clinical trial of [18F]FP-R01-MG-F2 in Idiopathic Pulmonary Fibrosis, sponsored by Stanford University.

Who is sponsoring NCT03183570?

NCT03183570 is sponsored by Stanford University.

What drugs are being tested in NCT03183570?

Interventions in NCT03183570: [18F]FP-R01-MG-F2.

Is NCT03183570 still recruiting?

NCT03183570 is currently completed. Last updated 4 February 2025.

Last reviewed 2025-02-04 · How we verify

NCT03183570

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

Completed EARLY_PHASE1 Last updated 4 February 2025

What this trial tests

EARLY_PHASE1 trial testing [18F]FP-R01-MG-F2 in Idiopathic Pulmonary Fibrosis in 21 participants. Completed in 25 January 2025.

Timeline

8 November 2017

Primary endpoint
25 April 2023

25 January 2025

Quick facts

Lead sponsor	Stanford University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	21
Start date	8 November 2017
Primary completion	25 April 2023
Estimated completion	25 January 2025
Sites	1 location across United States

Drugs / interventions tested

[18F]FP-R01-MG-F2 — full drug profile →

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →
Primary Sclerosing Cholangitis — all drugs for Primary Sclerosing Cholangitis →
Covid19 Pneumonia — all drugs for Covid19 Pneumonia →

Sponsor

Stanford University

Who can join

18 and older, any sex, with Idiopathic Pulmonary Fibrosis or Primary Sclerosing Cholangitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with \[18F\]FP-R01-MG-F2 with PET/CT

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting integrin pathways: mechanisms and advances in therapy.
Pang X, He X, Qiu Z, Zhang H, et al · · 2023 · cited 704× · PMID 36588107 · DOI 10.1038/s41392-022-01259-6
Emerging therapeutic opportunities for integrin inhibitors.
Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, et al · · 2022 · cited 394× · PMID 34535788 · DOI 10.1038/s41573-021-00284-4
Molecular imaging of fibrosis: recent advances and future directions.
Montesi SB, Désogère P, Fuchs BC, Caravan P. · · 2019 · cited 96× · PMID 30601139 · DOI 10.1172/jci122132
Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study).
Lukey PT, Coello C, Gunn R, Parker C, et al · · 2020 · cited 51× · PMID 31814068 · DOI 10.1007/s00259-019-04586-z
αV β6 Integrin: An Intriguing Target for COVID-19 and Related Diseases.
Bugatti K. · · 2021 · cited 10× · PMID 34132013 · DOI 10.1002/cbic.202100209
Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers.
Perez-Favila A, Garza-Veloz I, Hernandez-Marquez LDS, Gutierrez-Vela EF, et al · · 2024 · cited 9× · PMID 38338840 · DOI 10.3390/ijms25031562
Imaging in the COVID-19 era: Lessons learned during a pandemic.
Sideris GA, Nikolakea M, Karanikola AE, Konstantinopoulou S, et al · · 2021 · cited 7× · PMID 34249239 · DOI 10.4329/wjr.v13.i6.192

Verify or expand the search:

Other trials of [18F]FP-R01-MG-F2

Trials testing the same drug.

NCT02683824 — Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Vo · EARLY_PHASE1 · completed

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183570 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 4 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing